TwinBeech Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

TwinBeech Capital’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-102,768	Closed	-$895K	–	664
2024 Q1	$895K	Buy	102,768 +74,609	+265%	+$905K	0.02%	431
2023 Q4	$322K	Buy	+28,159	New	+$279K	0.01%	575
2023 Q2	–	Sell	-199,921	Closed	-$2.1M	–	732
2023 Q1	$2.1M	Buy	+199,921	New	+$2.24M	0.04%	370
2022 Q1	–	Sell	-104,627	Closed	-$1.22M	–	618
2021 Q4	$1.22M	Buy	+104,627	New	+$1.28M	0.07%	308
2021 Q1	–	Sell	-27,424	Closed	-$312K	–	554
2020 Q4	$312K	Buy	27,424 +14,493	+112%	+$159K	0.05%	360
2020 Q3	$116K	Sell	12,931 -14,071	-52%	-$140K	0.03%	398
2020 Q2	$279K	Buy	+27,002	New	+$276K	0.06%	300
2020 Q1	–	Sell	-17,621	Closed	-$235K	–	383
2019 Q4	$235K	Buy	+17,621	New	+$194K	0.07%	331

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

TwinBeech Capital's IRWD Position: Q2 2024 in Review

TwinBeech Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2024, closing a stake of 102,768 shares — an estimated $895K sold.

TwinBeech Capital first reported a position in IRWD in Q4 2019 and held it in 8 quarters. The position peaked at $2.1M in Q1 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q2 2024.

TwinBeech Capital reported no remaining Ironwood Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
TwinBeech Capital sold 102,768 Ironwood Pharmaceuticals shares in Q2 2024, an estimated $895K.
TwinBeech Capital first reported a position in Ironwood Pharmaceuticals in Q4 2019 and held it in 8 quarters.
TwinBeech Capital's Ironwood Pharmaceuticals position peaked at $2.1M in Q1 2023.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2024.

Based on TwinBeech Capital's 13F filing for Q2 2024, filed 14 Aug 2024.